Top Markets
#1 Islamic Coin Islamic Coin +151.48%
#2 DOVU DOVU +48.44%
#3 Black Phoenix Black Phoenix +34.78%
#4 Velvet Velvet +31.18%
#5 Cross Cross +22.50%
#6 Akedo Akedo +15.95%
#7 DoubleZero DoubleZero +14.89%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.53%
#9 Fake World Assets Fake World Assets +10.34%
#10 Cap Cap +10.26%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Classement en actions #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Prix de l'action
$17.15
Dernière synchronisation: 2026-08-03
Capitalisation boursière
$6.51M
Changement (1 jour)
9.80%
Changement (1 an)
289.77%
Pays
US
Échange Galera Therapeutics, Inc. (GRTX)

Catégorie

Healthcare
EPS pour Galera Therapeutics, Inc. (GRTX)
EPS au March 2026 TTM : $303.74
Selon les derniers rapports financiers et le cours de l'action de Galera Therapeutics, Inc., l’EPS actuel de la société (TTM) est de $303.74. À la fin de 2023, la société avait un EPS de $-1.33 une diminution par rapport à celui de 2022, qui était de $-2.30.
Historique de l'EPS de Galera Therapeutics, Inc. de 2017 à 2026
EPS à la fin de chaque année
Année EPS Changez
2026 (TTM) $303.74 -86,882.86%
2024 $-0.35 -73.68%
2023 $-1.33 -42.17%
2022 $-2.30 -32.35%
2021 $-3.40 14.09%
2020 $-2.98 42.58%
2019 $-2.09 71.31%
2018 $-1.22 7,770.97%
2017 $-0.02 0.00%
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -94.30%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -90.87%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -95.49%
BE